BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 17215146)

  • 1. RNA targeted therapeutics for hematologic malignancies.
    Gewirtz AM
    Blood Cells Mol Dis; 2007; 38(2):117-9. PubMed ID: 17215146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleic acid therapeutics for hematologic malignancies--theoretical considerations.
    Opalinska JB; Kalota A; Chattopadhyaya J; Damha M; Gewirtz AM
    Ann N Y Acad Sci; 2006 Oct; 1082():124-36. PubMed ID: 17145934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulation of the immune system by therapeutic antisense oligodeoxynucleotides and small interfering RNAs via nucleic acid receptors.
    Richardt-Pargmann D; Vollmer J
    Ann N Y Acad Sci; 2009 Sep; 1175():40-54. PubMed ID: 19796076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modulation of gene expression by antisense and antigene oligodeoxynucleotides and small interfering RNA.
    Mahato RI; Cheng K; Guntaka RV
    Expert Opin Drug Deliv; 2005 Jan; 2(1):3-28. PubMed ID: 16296732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical modification of gene silencing oligonucleotides for drug discovery and development.
    Chen X; Dudgeon N; Shen L; Wang JH
    Drug Discov Today; 2005 Apr; 10(8):587-93. PubMed ID: 15837602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic potential of antisense nucleic acid molecules.
    Opalinska JB; Gewirtz AM
    Sci STKE; 2003 Oct; 2003(206):pe47. PubMed ID: 14583589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myb targeted therapeutics for the treatment of human malignancies.
    Gewirtz AM
    Oncogene; 1999 May; 18(19):3056-62. PubMed ID: 10378701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical applications of aptamers and nucleic acid therapeutics in haematological malignancies.
    Shigdar S; Ward AC; De A; Yang CJ; Wei M; Duan W
    Br J Haematol; 2011 Oct; 155(1):3-13. PubMed ID: 21810089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma.
    Fuessel S; Meye A; Kraemer K; Kunze D; Hakenberg OW; Wirth MP
    Eur Urol; 2007 Feb; 51(2):315-26; discussion 326-7. PubMed ID: 16935415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotides for haematological malignancies.
    Cotter FE
    Haematologica; 1999 Jun; 84 Suppl EHA-4():19-22. PubMed ID: 10907458
    [No Abstract]   [Full Text] [Related]  

  • 12. Challenges and opportunities for local and systemic delivery of siRNA and antisense oligonucleotides.
    Sepp-Lorenzino L; Ruddy M
    Clin Pharmacol Ther; 2008 Nov; 84(5):628-32. PubMed ID: 18800034
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficiency of CD40 down regulation by siRNA and antisense ODN: comparison of lipofectamine and FuGENE6.
    Ebadi P; Karimi MH; Pourfathollah AA; Saheb Ghadam Lotfi A; Soheili ZS; Samiee S; Hajati S; Nadali F; Geramizadeh B; Moazzeni SM
    Iran J Immunol; 2009 Mar; 6(1):1-11. PubMed ID: 19293472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense oligonucleotides, aptamers and SiRNA: promises for the treatment of ocular diseases.
    Fattal E; Bochot A
    Arch Soc Esp Oftalmol; 2006 Jan; 81(1):3-4, 5-6. PubMed ID: 16450253
    [No Abstract]   [Full Text] [Related]  

  • 15. Oxetane modified, conformationally constrained, antisense oligodeoxyribonucleotides function efficiently as gene silencing molecules.
    Opalinska JB; Kalota A; Gifford LK; Lu P; Jen KY; Pradeepkumar PI; Barman J; Kim TK; Swider CR; Chattopadhyaya J; Gewirtz AM
    Nucleic Acids Res; 2004; 32(19):5791-9. PubMed ID: 15514112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sugar boost: when ribose modifications improve oligonucleotide performance.
    Faria M; Ulrich H
    Curr Opin Mol Ther; 2008 Apr; 10(2):168-75. PubMed ID: 18386229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense oligodeoxynucleotide-conjugated hyaluronic acid/protamine nanocomplexes for intracellular gene inhibition.
    Mok H; Park JW; Park TG
    Bioconjug Chem; 2007; 18(5):1483-9. PubMed ID: 17602578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of siRNA for therapeutics: efficient synthesis of phosphorothioate RNA utilizing phenylacetyl disulfide (PADS).
    Ravikumar VT; Andrade M; Carty RL; Dan A; Barone S
    Bioorg Med Chem Lett; 2006 May; 16(9):2513-7. PubMed ID: 16481168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeted delivery of therapeutic oligonucleotides to pulmonary circulation.
    Wilson A; He F; Li J; Ma Z; Pitt B; Li S
    Adv Genet; 2005; 54():21-41. PubMed ID: 16096006
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic oligonucleotides.
    Goodchild J
    Methods Mol Biol; 2011; 764():1-15. PubMed ID: 21748630
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.